The risk vs. benefit calculus of anticoagulation in patients with ibrutinib-related atrial fibrillation.
CLL
anticoagulation
atrial fibrillation
cardio-oncology
ibrutinib
stroke
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
Feb 2024
Feb 2024
Historique:
pmc-release:
01
02
2025
medline:
25
1
2024
pubmed:
13
11
2023
entrez:
13
11
2023
Statut:
ppublish
Résumé
For ibrutinib-related atrial fibrillation (IRAF), guidelines for anticoagulation do not exist. We sought to describe stroke, bleeding, and anticoagulation rates among patients with IRAF. We performed a single-center retrospective review of 168 patients treated with ibrutinib followed from 2013 to 2022. Over a median follow-up of 6.4 years, 44 (26.0%) patients developed IRAF of which 38 (86.4%) had a CHA2DS2-VASc ≥2 and 7 (15.9%) had a HAS-BLED ≥3. Anticoagulation was initiated in 20 (45.5%) without a clear pattern in scores, risk factors, or cumulative dose, besides having another reason for anticoagulation. Few patients with IRAF developed non-hemorrhagic CVA (
Identifiants
pubmed: 37953609
doi: 10.1080/10428194.2023.2278433
pmc: PMC10952122
mid: NIHMS1956429
doi:
Substances chimiques
ibrutinib
1X70OSD4VX
Anticoagulants
0
Adenine
JAC85A2161
Piperidines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
168-174Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001422
Pays : United States
Références
JACC CardioOncol. 2020 Dec 15;2(5):747-754
pubmed: 34396290
Blood. 2019 Nov 28;134(22):1919-1928
pubmed: 31582362
JACC CardioOncol. 2021 Mar 16;3(1):140-144
pubmed: 34396314
JACC Clin Electrophysiol. 2018 Dec;4(12):1491-1500
pubmed: 30573111
Am J Hypertens. 2017 Nov 1;30(11):1063-1065
pubmed: 28985289
Leuk Lymphoma. 2019 Jun;60(6):1447-1453
pubmed: 30730240
Blood. 2016 Jul 7;128(1):138-40
pubmed: 27247135
Cureus. 2018 May 29;10(5):e2701
pubmed: 30062075
Br J Haematol. 2017 Jul;178(2):286-291
pubmed: 28397242
Europace. 2017 Nov 1;19(11):1896-1902
pubmed: 29040554
JACC CardioOncol. 2023 Apr 18;5(2):233-243
pubmed: 37144107
Leuk Lymphoma. 2018 Feb;59(2):311-320
pubmed: 28629235
Blood Adv. 2017 Sep 08;1(20):1739-1748
pubmed: 29296820
J Am Coll Cardiol. 2019 Oct 1;74(13):1667-1678
pubmed: 31558250
Br J Haematol. 2016 Nov;175(3):462-466
pubmed: 27611233
Open Heart. 2019 May 8;6(1):e001049
pubmed: 31168393
Int J Cardiol. 2013 May 10;165(2):355-7
pubmed: 22989607
Haematologica. 2017 Oct;102(10):1796-1805
pubmed: 28751558
Circ Res. 2018 Jan 19;122(2):352-368
pubmed: 29348255
J Thromb Haemost. 2017 May;15(5):835-847
pubmed: 28182323
N Engl J Med. 2023 Jan 26;388(4):319-332
pubmed: 36511784
Leuk Lymphoma. 2017 Dec;58(12):2811-2814
pubmed: 28504030
J Clin Oncol. 2021 Nov 1;39(31):3441-3452
pubmed: 34310172
Curr Oncol Rep. 2019 Apr 4;21(5):45
pubmed: 30949848
Circulation. 2019 Jul 9;140(2):e125-e151
pubmed: 30686041
Int J Cardiol Heart Vasc. 2022 Jun 20;41:101072
pubmed: 35757148